| Reference |
Sentence |
Publish Date |
Extraction Date |
Species |
| Siegfried Kasper, Mark N Lerman, Robert D McQuade, Anutosh Saha, William H Carson, Mirza Ali, Donald Archibald, Gary Ingenito, Ronald Marcus, Teresa Pigot. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. The international journal of neuropsychopharmacology vol 6 issue 4 2004 14609439 |
the long-term efficacy and safety of aripiprazole (30 mg/d) relative to haloperidol (10 mg/d) were investigated in two 52-wk, randomized, double-blind, multicentre studies (using similar protocols which were prospectively identified to be pooled for analysis) in 1294 patients in acute relapse with a diagnosis of chronic schizophrenia and who had previously responded to antipsychotic medications. |
2004-05-06 |
2023-01-24 |
Not clear |
| Siegfried Kasper, Mark N Lerman, Robert D McQuade, Anutosh Saha, William H Carson, Mirza Ali, Donald Archibald, Gary Ingenito, Ronald Marcus, Teresa Pigot. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. The international journal of neuropsychopharmacology vol 6 issue 4 2004 14609439 |
aripiprazole represents a promising new option for the long-term treatment of schizophrenia. |
2004-05-06 |
2023-01-24 |
Not clear |
| S M Stahl, M M Grad. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Current medicinal chemistry vol 11 issue 3 2004 14965234 |
the atypical antipsychotics risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole have become first-line treatment for schizophrenia because they reduce the positive symptoms of psychosis but do not have a high incidence of extrapyramidal symptoms. |
2004-04-20 |
2023-01-24 |
Not clear |
| Elizabeth Winan. Aripiprazole. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists vol 60 issue 23 2004 14686220 |
aripiprazole is a third-generation antipsychotic agent indicated for use in the treatment of schizophrenia. |
2004-03-19 |
2023-01-24 |
Not clear |
| Elizabeth Winan. Aripiprazole. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists vol 60 issue 23 2004 14686220 |
in controlled, randomized, multicenter trials, aripiprazole has demonstrated efficacy in the treatment of schizophrenia comparable to that of haloperidol and superior to placebo. |
2004-03-19 |
2023-01-24 |
Not clear |
| Elizabeth Winan. Aripiprazole. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists vol 60 issue 23 2004 14686220 |
aripiprazole offers an alternative to second-generation antipsychotic agents in the treatment of schizophrenia. |
2004-03-19 |
2023-01-24 |
Not clear |
| James P Kellehe. Aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder. Evidence-based mental health vol 7 issue 1 2004 14769657 |
aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder. |
2004-03-01 |
2023-01-24 |
Not clear |
| Teresa A Pigott, William H Carson, Anutosh R Saha, Anne F Torbeyns, Elyse G Stock, Gary G Ingenit. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. The Journal of clinical psychiatry vol 64 issue 9 2004 14628980 |
aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. |
2004-02-17 |
2023-01-24 |
Not clear |
| Teresa A Pigott, William H Carson, Anutosh R Saha, Anne F Torbeyns, Elyse G Stock, Gary G Ingenit. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. The Journal of clinical psychiatry vol 64 issue 9 2004 14628980 |
aripiprazole is a novel antipsychotic for the management of schizophrenia. |
2004-02-17 |
2023-01-24 |
Not clear |
| Teresa A Pigott, William H Carson, Anutosh R Saha, Anne F Torbeyns, Elyse G Stock, Gary G Ingenit. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. The Journal of clinical psychiatry vol 64 issue 9 2004 14628980 |
this study investigated the efficacy, safety, and tolerability of aripiprazole in preventing relapse in adult chronic schizophrenia patients experiencing ongoing stable symptomatology. |
2004-02-17 |
2023-01-24 |
Not clear |
| Stephen R Marder, Robert D McQuade, Elyse Stock, Stephen Kaplita, Ronald Marcus, Allan Z Safferman, Anutosh Saha, Mirza Ali, Taro Iwamot. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia research vol 61 issue 2-3 2003 12729864 |
aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. |
2003-12-09 |
2023-01-24 |
Not clear |
| Stephen R Marder, Robert D McQuade, Elyse Stock, Stephen Kaplita, Ronald Marcus, Allan Z Safferman, Anutosh Saha, Mirza Ali, Taro Iwamot. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia research vol 61 issue 2-3 2003 12729864 |
presented here is a pooled analysis of safety and tolerability data from all completed short-term, placebo-controlled trials in schizophrenia from the aripiprazole clinical development program. |
2003-12-09 |
2023-01-24 |
Not clear |
| Stephen R Marder, Robert D McQuade, Elyse Stock, Stephen Kaplita, Ronald Marcus, Allan Z Safferman, Anutosh Saha, Mirza Ali, Taro Iwamot. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia research vol 61 issue 2-3 2003 12729864 |
data were analyzed from five 4- to 6-week double-blind multicenter studies of patients hospitalized with acute relapse of schizophrenia or schizoaffective disorder randomized to aripiprazole (n=932), placebo (n=416), or haloperidol (n=201). |
2003-12-09 |
2023-01-24 |
Not clear |
| Stephen R Marder, Robert D McQuade, Elyse Stock, Stephen Kaplita, Ronald Marcus, Allan Z Safferman, Anutosh Saha, Mirza Ali, Taro Iwamot. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia research vol 61 issue 2-3 2003 12729864 |
aripiprazole's safety profile may offer benefits in schizophrenia treatment. |
2003-12-09 |
2023-01-24 |
Not clear |
| Martha Sajatovi. Treatment for mood and anxiety disorders: quetiapine and aripiprazole. Current psychiatry reports vol 5 issue 4 2003 12857536 |
aripiprazole was recently approved for the treatment of schizophrenia by the us food and drug administration in late 2002, and is being used increasingly in clinical settings. |
2003-12-09 |
2023-01-24 |
Not clear |
| Steven G Potkin, Anutosh R Saha, Mary J Kujawa, William H Carson, Mirza Ali, Elyse Stock, Joseph Stringfellow, Gary Ingenito, Stephen R Marde. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of general psychiatry vol 60 issue 7 2003 12860772 |
aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. |
2003-09-16 |
2023-01-24 |
Not clear |
| Steven G Potkin, Anutosh R Saha, Mary J Kujawa, William H Carson, Mirza Ali, Elyse Stock, Joseph Stringfellow, Gary Ingenito, Stephen R Marde. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of general psychiatry vol 60 issue 7 2003 12860772 |
this multicenter trial examined the efficacy, safety, and tolerability of aripiprazole in patients with acute exacerbation of schizophrenia or schizoaffective disorder. |
2003-09-16 |
2023-01-24 |
Not clear |
| W W Fleischhacke. New developments in the pharmacotherapy of schizophrenia. Journal of neural transmission. Supplementum vol issue 64 2003 12830932 |
while the concept of partial d1-agonism has already led to the successful launch of a new antipsychotic, aripiprazole, the other attempts to improve therapeutic response in schizophrenia patients have so far provided equivocal results. |
2003-08-06 |
2023-01-24 |
Not clear |
| Toya M Bowles, Gary M Levi. Aripiprazole: a new atypical antipsychotic drug. The Annals of pharmacotherapy vol 37 issue 5 2003 12708948 |
to review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of aripiprazole for the treatment of schizophrenia. |
2003-06-23 |
2023-01-24 |
Not clear |
| D M Taylo. Aripiprazole: a review of its pharmacology and clinical use. International journal of clinical practice vol 57 issue 1 2003 12587943 |
once-daily aripiprazole 15-30 mg is as effective as haloperidol 10 mg/day and risperidone 6 mg/day in short-term treatment of schizophrenia and more effective than haloperidol 7-10 mg/day in maintenance of response in chronic schizophrenia. |
2003-05-19 |
2023-01-24 |
Not clear |